Trimel Announces Closing of Exclusive Agreement for NATESTO(TM)
Marketwired - Tue Dec 09, 6:01AM CST
Trimel Pharmaceuticals Corporation (TSX: TRL) today announced the closing of the previously communicated agreement between its subsidiary, Trimel BioPharma SRL, and an affiliate of Endo International plc (NASDAQ: ENDP)(TSX: ENL), of which Endo has been granted the exclusive rights to market NATESTO(TM) in the United States and Mexico. Trimel has received an upfront payment of US$25 million on closing of the transaction, together with a US$5 million prepaid inventory deposit.
ENDP: 67.73 (+0.46), ENL.TO: 80.31 (+0.66), TRL.TO: 0.69 (-0.01)
Endo to Acquire Rights to Testosterone Nasal Gel Natesto - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 25, 5:00PM CST
Endo International announced that it has entered into an agreement to acquire the rights to Natesto from Trimel Pharmaceuticals Corporation.
ENDP: 67.73 (+0.46), ACT: 256.52 (-6.48), AMAG: 40.30 (+1.29)
Trimel Announces Issuance of Additional Patent Covering NATESTO(TM)
Marketwired - Tue Nov 25, 12:01PM CST
Trimel Pharmaceuticals Corporation (TSX: TRL) today announced that its technology partner Mattern Pharma AG has been granted an additional United States Patent in respect of NATESTO(TM) and its proprietary nasal gel technology. Trimel expects one or more claims in such patent to be eligible for listing in the Food and Drug Administration (FDA) Orange Book in connection with NATESTO(TM). The Orange Book is the FDA's database of Approved Drug Products with Therapeutic Equivalence Evaluations.
TRL.TO: 0.69 (-0.01)
Trimel announces grant of marketing rights of NATESTO to Endo International
M2 - Tue Nov 25, 8:49AM CST
Specialist pharmaceutical company Trimel Pharmaceuticals (TSX:TRL.TO) disclosed on Monday that it has entered into an agreement to grant the exclusive rights to market NATESTO in the US and Mexico, subject to customary Hart-Scott-Rodino approval.
ENDP: 67.73 (+0.46)
Trimel Announces Exclusive License Agreement With Endo for NATESTO(TM)
Marketwired - Mon Nov 24, 6:01AM CST
Trimel Pharmaceuticals Corporation (TSX: TRL) today announced the signing of an agreement by its subsidiary, Trimel Biopharma SRL, providing an affiliate of Endo International plc (NASDAQ: ENDP) (TSX: ENL) with the exclusive rights to market NATESTO(TM) in the United States and Mexico. NATESTO(TM) is the first and only FDA-approved testosterone nasal gel indicated for replacement therapy in adult males diagnosed with hypogonadism.
ENDP: 67.73 (+0.46), ENL.TO: 80.31 (+0.66), TRL.TO: 0.69 (-0.01)
Endo Acquires Rights to Natesto(TM) Testosterone Nasal Gel
PR Newswire - Mon Nov 24, 6:00AM CST
FDA-approved product further expands Endo's Branded Pharmaceutical Men's Health portfolio
ENDP: 67.73 (+0.46), ENL.TO: 80.31 (+0.66), TRL.TO: 0.69 (-0.01)
CORRECTION FROM SOURCE: Trimel Reports Third Quarter 2014 Financial Results
Marketwire Canada - Thu Nov 06, 10:37AM CST
Trimel Pharmaceuticals Corporation (TSX:TRL) -
TRL.TO: 0.69 (-0.01)
Trimel Reports Third Quarter 2014 Financial Results
Marketwired - Thu Nov 06, 7:09AM CST
Trimel Pharmaceuticals Corporation (TSX: TRL) today reported financial results for the three month period ended September 30, 2014 and highlighted important corporate activities. Unless otherwise noted, all dollars amounts shown in this press release are in U.S. dollars.
TRL.TO: 0.69 (-0.01)
Trimel to Report Third Quarter 2014 Results and Host Conference Call to Update Investors
Marketwired - Wed Oct 29, 4:06PM CDT
Trimel Pharmaceuticals Corporation (TSX: TRL) will report its third quarter financial results for the period ended September 30, 2014 on Thursday, November 6, 2014 before markets open.
TRL.TO: 0.69 (-0.01)
First Generation Capital Inc. Converts a Portion of Previously Issued Convertible Note of Trimel Pharmaceuticals Corporation
Marketwire - Fri Aug 22, 5:28PM CDT
Mr. Ian Ihnatowycz announced that effective today, he has converted US$5,151,768.08 aggregate amount (of which US$55,002.59 was accrued interest) of obligations owing under the convertible note (the "Note"
Trimel Announces New TriVair(TM) Website
Marketwire - Thu Jul 31, 4:06PM CDT
Trimel Pharmaceuticals Corporation (TSX: TRL) announced today that the Company has launched a new website for its dry powder inhalation drug delivery platform TriVair(TM). Winner of the 2009 European Drug Delivery Product Differentiation Innovation of the Year Award, TriVair(TM) is Trimel's novel unit-dose dry powder inhaler / nasal dispersion device. Trimel is interested in establishing partnership arrangements with developers who are looking for a patented, novel dry powder nasal and pulmonary delivery system. For more information, please visit www.trivairdevice.com.
TRL.TO: 0.69 (-0.01)
Trimel Provides Corporate Update and Second Quarter 2014 Financial Results
Marketwire - Wed Jul 30, 5:04PM CDT
Trimel Pharmaceuticals Corporation (TSX: TRL) today provided an overview of its corporate accomplishments and reported financial results for the three month period ended June 30, 2014.
SHPG: 208.76 (+0.28), TRL.TO: 0.69 (-0.01)